Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2055273 | 0.93 | PAX8 (0.50) | APPSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL23364361 | 0.88 | APP (0.53) | APPSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL29874189 | 0.88 | APP (0.53) | APPSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL27173135 | 0.88 | PIK3CA (0.40) | APPSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL2100954 | 0.84 | APP (0.46) | APPSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL2100061 | 0.84 | PAX8 (0.60) | APPMAPTNPC1RAB9AKDM4E | |
| SCHEMBL4168564 | 0.83 | APP (0.49) | APPSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL29453156 | 0.81 | PAX8 (0.41) | APPSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL29453212 | 0.80 | APP (0.44) | APPSMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL2100953 | 0.79 | APP (0.45) | APPSMN1; SMN2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957215-B2 | Heteroaryl substituted benzothiazoles | NAVIDEA BIOPHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20120207679-A1 | Novel Heteroaryl Substituted Benzothiazoles | ASTRAZENECA AB (SE) | 2012-08-16 | — | — | US | disclosed |
| US-20090028787-A1 | Novel Heteroaryl Substituted Benzothiazoles | NAVIDEA BIOPHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1981883-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES | AstraZeneca AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007086800-A1 | NOVEL HETEROARYL SUBSTITUTED BENZOTHIAZOLES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090028787-A1 | Novel Heteroaryl Substituted Benzothiazoles | APP, MAPT, PSEN1 | APP 1/4885SMN1; SMN2 1164/4885MAPT 2/4885 |
| US-20120207679-A1 | Novel Heteroaryl Substituted Benzothiazoles | MAPT, APP, PSEN1 | APP 2/4885SMN1; SMN2 1170/4885MAPT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.